Pulmonx Corporation  (LUNG)
Other Ticker:  
Price: $8.0700 $-0.31 -3.699%
Day's High: $8.92 Week Perf: -9.53 %
Day's Low: $ 7.95 30 Day Perf: 10.55 %
Volume (M): 272 52 Wk High: $ 14.84
Volume (M$): $ 2,197 52 Wk Avg: $10.92
Open: $8.40 52 Wk Low: $7.11

 Market Capitalization (Millions $) 312
 Shares Outstanding (Millions) 39
 Employees -
 Revenues (TTM) (Millions $) 71
 Net Income (TTM) (Millions $) -59
 Cash Flow (TTM) (Millions $) -40
 Capital Exp. (TTM) (Millions $) 1

Pulmonx Corporation
Pulmonx Corporation is a medical technology company that specializes in developing and commercializing minimally invasive solutions for patients with severe lung diseases. The company focuses on providing innovative treatments for conditions such as chronic obstructive pulmonary disease (COPD) and severe emphysema. Its flagship product is the Zephyr Valve system, which is designed to improve lung function by blocking off diseased lung regions and allowing healthier lung tissue to function more effectively. Pulmonx Corporation is dedicated to improving the quality of life for patients with lung diseases by offering less invasive and highly effective treatment options.

   Company Address: 700 Chesapeake Drive Redwood City 94063 CA
   Company Phone Number: 364-0400   Stock Exchange / Ticker: NASDAQ LUNG


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Financing Agreement

Pulmonx Corporation Grants Inducement Awards to New Chief Financial Officer

Published Mon, May 6 2024 9:03 PM UTC

Pulmonx Corporation Grants Inducement Awards to New Chief Financial Officer
Pulmonx Corporation, a leading global provider of minimally invasive treatments for lung disease, recently announced the granting of inducement awards to Mehul Joshi, who was appointed as the company's Chief Financial Officer in April 2024. The awards, approved by the Compensation Committee of th...

Pulmonx Corporation

Pulmonx Corporation Struggles with Financial Performance Amid Revenue Surge: A Closer Look at the $-0.36 Per Share Shortfall

Pulmonx Corporation, a global leader in minimally invasive treatments for lung disease, has recently reported a surge in revenue in its Mar 31, 2024 report. However, the company's financial performance remains deeply concerning, with a net loss of $-0.36 per share and an overall revenue deterioration by -7.073% from the previous year. This bearish article aims to analyze the financial struggles faced by Pulmonx Corporation, their recent appointment of a new Chief Financial Officer (CFO), and the outlook for the company's future prospects.
Deteriorating Financial Situation:
In its recent financial report, Pulmonx Corporation announced a revenue increase of 24.376% to $18.08 million from the corresponding period the previous year. However, the company still reported a loss of $-0.36 per share, indicating an alarming trend in profitability. Furthermore, the revenue decline of -7.073% from $19.45 million raises concerns about the sustainability of Pulmonx Corporation's financial health. These figures highlight a significant deterioration in the company's financial situation.

Management Changes

Pulmonx Corporation Instills Financial Expertise with New CFO Appointment, Aiming for Future Recovery and Innovation

Published Tue, Apr 2 2024 8:05 PM UTC

Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer: Assessing the Company's Financial Situation and Future Prospects
Pulmonx Corporation, a leader in minimally invasive treatments for lung disease, has recently appointed Mehul Joshi as its new Chief Financial Officer. The appointment comes after Pulmonx recorded a cumulative net loss of $-61 million...

Pulmonx Corporation

Pulmonx Corporation's Revenue Skyrockets in Q4, 2023

As a financial journalist with the , I have been closely following the latest financial results of Pulmonx Corporation for the fourth quarter of 2023. The company, specializing in minimally invasive treatments for lung disease, has seen some positive improvements in their financial performance compared to the previous year.
One key highlight from the financial results is the decrease in loss per share from $-0.37 to $-0.35, as well as an improvement in earnings per share from $-0.39 in the prior reporting season. The revenue has also shown significant growth, with a rapid increase of 26.12% to $19.45 million from $15.43 million in the similar reporting season a year before.

Pulmonx Corporation

Pulmonx Corporation Sees Impressive Revenue Surge of 26.122% in Q3 2023, But Profitability Remains Elusive

Pulmonx Corporation, a global leader in minimally invasive treatments for lung disease, recently released its financial report for the third quarter of 2023. The report showcased some interesting figures, reflecting the company's growth and challenges.
One remarkable highlight is the surge in revenue by 26.122%, amounting to $17.03 million compared to the previous year's financial reporting period. This growth indicates Pulmonx's ability to attract more customers and generate higher income. However, despite the increase in revenue, the company experienced a widening deficit of $-0.39 per share. This implies that the expenses incurred by Pulmonx are currently exceeding its earnings per share.


Pulmonx's Segments
• View Complete Report
  Company Estimates  
  Revenue Outlook
Pulmonx does not provide revenue guidance.

Earnings Outlook
Pulmonx Corporation does not provide earnings estimates.

Geographic Revenue Dispersion


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com